Related references
Note: Only part of the references are listed.First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies
Sandra M. M. Irenaeus et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Immunoreduction of ocular surface tumours with intralesional interferon alpha-2a
S. E. Kim et al.
EYE (2018)
Intralesional anti-PD1 treatment in patients with metastatic melanoma: The pilot study.
Igor Samoylenko et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Evaluation of T-lymphocyte subpopulations in actinic keratosis, in situ and invasive squamous cell carcinoma of the skin
Aristea Stravodimou et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2018)
T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model
Hao Liu et al.
PLOS ONE (2018)
Electrochemotherapy in the treatment of melanoma
Mateusz Wichtowski et al.
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY (2018)
Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma
Mohammed Milhem et al.
CANCER RESEARCH (2018)
Interim analysis of a randomized, open-label phase 2 study of talimogene laherparepvec (T-VEC) neoadjuvant treatment (neotx) plus surgery (surgx) vs surgx for resectable stage IIIB-IVM1a melanoma (MEL)
Robert Hans Ingemar Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Calcium electroporation for treatment of cutaneous metastases; a randomized double-blinded phase II study, comparing the effect of calcium electroporation with electrochemotherapy
H. Falk et al.
ACTA ONCOLOGICA (2018)
Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid)
David A. Canton et al.
IMMUNOTHERAPY (2017)
Effective melanoma cancer suppression by iontophoretic co-delivery of STAT3 siRNA and imatinib using gold nanoparticles
Suman Labala et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2017)
Clinical Response Rates From Interleukin-2 Therapy for Metastatic Melanoma Over 30 Years' Experience: A Meta-Analysis of 3312 Patients
Richard Bright et al.
JOURNAL OF IMMUNOTHERAPY (2017)
CYP4A in tumor-associated macrophages promotes pre-metastatic niche formation and metastasis
X. W. Chen et al.
ONCOGENE (2017)
Simulated Sunlight-Mediated Photodynamic Therapy for Melanoma Skin Cancer by Titanium-Dioxide-Nanoparticle-Gold-Nanocluster-Graphene Heterogeneous Nanocomposites
Yan Cheng et al.
SMALL (2017)
Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting
Eva Pike et al.
BMJ OPEN (2017)
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
Paul C. Tumeh et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Mycobacterium bovis Bacillus calmette-guerin alters Melanoma Microenvironment Favoring antitumor T cell responses and improving M2 Macrophage Function
Ricardo D. Lardone et al.
FRONTIERS IN IMMUNOLOGY (2017)
Activity of a novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients previously treated with anti-PD1 blockade therapy.
Brendan D. Curti et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Immunotherapy with imiquimod and interferon alfa for metastasized Merkel cell carcinoma
R. U. Wahl et al.
CURRENT ONCOLOGY (2016)
Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma
Robert H. I. Andtbacka et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2016)
Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma
Adil I. Daud et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase
Takashi Inozume et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma
Abhijit Ray et al.
ONCOTARGET (2016)
TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection
Glen M. Chew et al.
PLOS PATHOGENS (2016)
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study
Riccardo Danielli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-γ) in metastatic melanoma patients
Amir Khammari et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Synthetic Nanoparticles for Vaccines and Immunotherapy
Darrell J. Irvine et al.
CHEMICAL REVIEWS (2015)
TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients
Joe-Marc Chauvin et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Naive T Cell Maintenance and Function in Human Aging
Joerg J. Goronzy et al.
JOURNAL OF IMMUNOLOGY (2015)
100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series
Vivian Y. Shi et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
Juan Fu et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Intratumoral Thermal Reading During Photo-Thermal Therapy by Multifunctional Fluorescent Nanoparticles
Elisa Carrasco et al.
ADVANCED FUNCTIONAL MATERIALS (2015)
Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma
John F. Thompson et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
A phase I study of intratumoral injection of ipilimumab and interleukin-2 in patients with unresectable stage III-IV melanoma.
Randy Christopher Bowen et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+ T Cell Effector Function
Robert J. Johnston et al.
CANCER CELL (2014)
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
Dmitriy Zamarin et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19-IL2 Results in Sustained Clinical and Systemic Immunologic Responses
Benjamin Weide et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Downregulation of MHC-I Expression Is Prevalent but Reversible in Merkel Cell Carcinoma
Kelly G. Paulson et al.
CANCER IMMUNOLOGY RESEARCH (2014)
CALM study: A phase 11 study of an intratumorally delivered oncolytic immunotherapeutic agent, coxsackievirus A21, in patients with stage Ilk and stage IV malignant melanoma.
Robert Hans Ingemar Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Systemic antitumor effect and clinical response in a phase 2 trial of intratumoral electroporation of plasmid interleukin-12 in patients with advanced melanoma.
Adil Daud et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma
Stephen R. Goding et al.
JOURNAL OF IMMUNOLOGY (2013)
Combined TLR7/8 and TLR9 Ligands Potentiate the Activity of a Schistosoma japonicum DNA Vaccine
Xuefeng Wang et al.
PLOS NEGLECTED TROPICAL DISEASES (2013)
Electrochemotherapy for disseminated superficial metastases from malignant melanoma
L. G. Campana et al.
BRITISH JOURNAL OF SURGERY (2012)
Tumor Infiltrating Immune Cells and Outcome of Merkel Cell Carcinoma: A Population-Based Study
Harri Sihto et al.
CLINICAL CANCER RESEARCH (2012)
Microneedle-Based Intradermal Delivery Enables Rapid Lymphatic Uptake and Distribution of Protein Drugs
Alfred J. Harvey et al.
PHARMACEUTICAL RESEARCH (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Origin of the Lamina Propria Dendritic Cell Network
Milena Bogunovic et al.
IMMUNITY (2009)
Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor-Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
Neil N. Senzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The origin and development of nonlymphoid tissue CD103+ DCs
Florent Ginhoux et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
Brian G. Till et al.
BLOOD (2008)
Novel Jet-Injection Technology for Nonviral Intratumoral Gene Transfer in Patients with Melanoma and Breast Cancer
Wolfgang Walther et al.
CLINICAL CANCER RESEARCH (2008)
Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma
Adil I. Daud et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Transdermal drug delivery
Mark R. Prausnitz et al.
NATURE BIOTECHNOLOGY (2008)
Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate
Guenther F. L. Hofbauer et al.
MELANOMA RESEARCH (2008)
Chemoablation of metastatic melanoma using intralesional Rose Bengal
John F. Thompson et al.
MELANOMA RESEARCH (2008)
Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells
Miriam Merad et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma
D. S. Green et al.
BRITISH JOURNAL OF DERMATOLOGY (2007)
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor
Jennifer C. C. Hu et al.
CLINICAL CANCER RESEARCH (2006)
Treatment of basal cell carcinoma located in the head and neck region with intralesional interferon alpha-2a - Evaluation of long-term follow-up results
S Bostanci et al.
CLINICAL DRUG INVESTIGATION (2005)
The CD8α+ dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens
GT Belz et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway
H Hemmi et al.
NATURE IMMUNOLOGY (2002)
Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens
N Kadowaki et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Share Paper
